GlassScriptPhysician profile
Dean Kirkel
NPI 1740242932
$43,602.77
in general payments reported to CMS, 2019-2025
40 companies · $5,951 in 2025
The $5,951 reported for 2025 was more than what 84% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,989 · 2020: $11K · 2021: $2,366 · 2022: $6,677 · 2023: $8,084 · 2024: $3,201 · 2025: $5,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,635 · Travel and Lodging: $1,460 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,123.00 |
| Food and Beverage | $1,634.64 |
| Travel and Lodging | $1,460.31 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $8,032.79 | 2019-2025 | Darzalex |
| Kite Pharma, INC. | $7,323.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $4,100.23 | 2020-2021 | |
| Deciphera Pharmaceuticals INC. | $4,053.42 | 2023-2024 | Qinlock |
| Pfizer INC. | $3,980.66 | 2019-2025 | |
| Incyte Corporation | $3,819.62 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $2,855.91 | 2019-2024 | Eliquis |
| Puma Biotechnology, INC. | $2,180.00 | 2020 | |
| Seagen INC. | $1,886.51 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Karyopharm Therapeutics INC. | $1,550.00 | 2020 | |
| Rigel Pharmaceuticals, INC. | $1,000.00 | 2020 | |
| Celgene Corporation | $968.82 | 2021-2025 | Reblozyl |
| Beigene, LTD. | $450.00 | 2020 | |
| Intera Oncology, INC | $222.50 | 2024 | Intera |
| Ipsen Biopharmaceuticals, INC | $211.35 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $152.47 | 2019-2021 | |
| Abbvie INC. | $151.65 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $141.91 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $104.62 | 2019-2022 | |
| Astellas Pharma US INC | $68.77 | 2021-2025 | Padcev |
| Daiichi Sankyo INC. | $49.88 | 2024 | Enhertu |
| Janssen Biotech, INC. | $49.16 | 2019-2025 | Darzalex |
| Tersera Therapeutics LLC | $44.66 | 2019 | |
| Eisai INC. | $38.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.79 | 2019-2020 | |
| Stemline Therapeutics INC. | $25.80 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $18.94 | 2024 | Enhertu |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Genentech USA, INC. | $15.62 | 2019 | |
| Genzyme Corporation | $15.34 | 2019 | |
| Exelixis INC. | $12.15 | 2020 | |
| Amgen INC. | $11.93 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.36 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Kirkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.